Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 16;55(4):361-369.
doi: 10.14744/TurkPediatriArs.2020.01700. eCollection 2020.

Effect of gonadotropin-releasing hormone analog treatment on final height in girls aged 6-10 years with central precocious and early puberty

Pınar Şimşek Onat  1 , Şenay Savaş Erdeve  2 , Semra Çetinkaya  2 , Zehra Aycan  2
Affiliations

Effect of gonadotropin-releasing hormone analog treatment on final height in girls aged 6-10 years with central precocious and early puberty

Pınar Şimşek Onat et al. Turk Pediatri Ars. .

Abstract
in English, Turkish

Aim: To determine the effects of gonadotropin-releasing hormone analog treatment on final height and body mass index in girls with central precocious puberty.

Material and methods: All cases with diagnosis age <8 years constituted group 1 (n=19) and those with ≥8 years constituted group 2 (n=35).

Results: There was no significant difference in height standard deviation score, body mass index standard deviation score, bone age/chronologic age, predicted final height at the time of diagnosis, and follow-up between group 1 and group 2. There was no significant difference in final height (standard deviation score) between the groups. The number of obese and overweight cases at diagnosis and final height was similar. The target height (standard deviation score), predicted final height (standard deviation score), and final height (standard deviation score) were similar in both Group 1 and Group 2.

Conclusion: We found that between the ages of 6-9.8 years, girls with central precocious puberty who received gonadotropin-releasing hormone analog treatment reached a final height within their target height range. It is concluded that gonadotropin-releasing hormone analog treatment increases body mass index during treatment and when patients reach the final height, they return to their pretreatment body mass index. Younger age and greater height at the time of diagnosis are the positive factors on final height.

Amaç: Santral erken puberteli olgularda Gonadotropin Releasing Hormon agonist tedavisinin final boy ve vücut kitle indeksi üzerine etkisinin değerlendirilmesini amaçladık.

Gereç ve yöntemler: Çalışmaya alınan 54 kız hasta tanı yaşlarına göre 2 gruba ayrıldı. Tanı yaşı 8 yaş altı olan olgular Grup 1’i, 8 yaş ve üzeri olan olgular Grup 2’yi oluşturdu. Grup 1’de 19 hasta, Grup 2’de 35 hasta vardı.

Bulgular: Tanıda ve izlem yıllarında boy standart deviasyon skoru, vücut kitle indeksi standart deviasyon skoru, kemik yaşı/takvim yaşı, öngörülen son boy açısından Grup 1 ile Grup 2 arasında istatistiksel olarak anlamlı fark yoktu. Gruplar arasında final boy, final boy standart deviasyon skoru açısından fark yoktu. Tanıda ve finalde obez ve kilolu olgu sayısı benzerdi. Hem Grup 1 hem Grup 2’de hedef boy, öngörülen son boy ve final boylar arasında ve bunların standart deviasyon skorları arasında istatistiksel olarak anlamlı fark saptanmadı.

Çikarimlar: Bu çalışmada Gonadotropin Releasing Hormon agonist tedavisi verilen 6–9.8 yaş aralığındaki santral erken puberteli kızların hedef boyları ile uyumlu final boya ulaştıkları belirlendi. Gonadotropin Releasing Hormon agonist tedavisinin tedavi sırasında vücut kitle indeksini arttırdığı, tedavi kesiminden sonra final boya ulaşıldığında hastaların tanı vücut kitle indekslerine geri döndükleri sonucuna varıldı. Tanı yaşının küçük olması ve tanı boyunun uzun olması final boy üzerine pozitif etkili etmenler olduğu bulundu.

Keywords: Central precocious puberty; early puberty; final height; gonadotropin-releasing hormone analog treatment; rapidly progressive puberty.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Comparisons of target height, PFH and final height within the Group 1 and Group 2
Figure 2
Figure 2
Comparisons of TH SDS, PFH SDS and Final height SDS within the Group 1 and Group 2
Figure 3
Figure 3
Comparisons of BW SDS at diagnosis and follow up in Group 1 andGroup 2
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lee PA, Houk CP. Puberty and Its Disorders. In: Liftshitz F, editor. Pediatric Endocrinology. New York, USA: Informa Healthcare Inc; 2007. pp. 274–90.
    1. Parent AS, Teilmann G, Juul A, Skakkebaek NE, Toppari J, Bourguignon JP. The timing of normal puberty and the age limits of sexual precocity:variations around the world, secular trends, and changes after migration. Endocr Rev. 2003;24:668–93. - PubMed
    1. Jung MK, Song KC, Kwon AR, Chae HW, Kim DH, Kim HS. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone. Ann Pediatr Endocrinol Metab. 2014;19:214–9. - PMC - PubMed
    1. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB., Jr Increased final height in precocious puberty after long-term treatment with LHRH agonists:the National Institutes of Health experience. J Clin Endocrinol Metab. 2001;86:4711–6. - PubMed
    1. Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab. 2007;92:3483–9. - PubMed

LinkOut - more resources